Overview

Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance

Status:
Completed

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

Insulin resistance is common in people coinfected with HIV and Hepatitis C virus (HCV) and is associated with poor responses to treatment for HCV. Pioglitazone is an FDA-approved medication for the treatment of type 2 diabetes. It works by increasing the body's sensitivity to insulin. The purpose of this study is to determine whether treatment with pioglitazone prior to HCV treatment with peginterferon and ribavirin is safe and effective in improving the treatment outcome in insulin-resistant, HIV/HCV-coinfected people for whom previous treatment with peginterferon and ribavirin was unsuccessful.

Phase:

Phase 2

Details

Lead Sponsor:

AIDS Clinical Trials Group

Collaborator:

National Institute of Allergy and Infectious Diseases (NIAID)

Treatments:

Insulin
Pioglitazone
Ribavirin